JP2014224126A5 - - Google Patents

Download PDF

Info

Publication number
JP2014224126A5
JP2014224126A5 JP2014143781A JP2014143781A JP2014224126A5 JP 2014224126 A5 JP2014224126 A5 JP 2014224126A5 JP 2014143781 A JP2014143781 A JP 2014143781A JP 2014143781 A JP2014143781 A JP 2014143781A JP 2014224126 A5 JP2014224126 A5 JP 2014224126A5
Authority
JP
Japan
Prior art keywords
peptide
composition
carrier
group
cargo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014143781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014224126A (ja
JP5937643B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014224126A publication Critical patent/JP2014224126A/ja
Publication of JP2014224126A5 publication Critical patent/JP2014224126A5/ja
Application granted granted Critical
Publication of JP5937643B2 publication Critical patent/JP5937643B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014143781A 2007-01-19 2014-07-14 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 Active JP5937643B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88141907P 2007-01-19 2007-01-19
US60/881,419 2007-01-19
US94528507P 2007-06-20 2007-06-20
US60/945,285 2007-06-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009546577A Division JP2010516707A (ja) 2007-01-19 2008-01-22 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016096016A Division JP2016147905A (ja) 2007-01-19 2016-05-12 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Publications (3)

Publication Number Publication Date
JP2014224126A JP2014224126A (ja) 2014-12-04
JP2014224126A5 true JP2014224126A5 (enExample) 2015-07-16
JP5937643B2 JP5937643B2 (ja) 2016-06-22

Family

ID=39636771

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2009546577A Ceased JP2010516707A (ja) 2007-01-19 2008-01-22 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2014143781A Active JP5937643B2 (ja) 2007-01-19 2014-07-14 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2016096016A Pending JP2016147905A (ja) 2007-01-19 2016-05-12 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2018058012A Pending JP2018111717A (ja) 2007-01-19 2018-03-26 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2021036134A Pending JP2021098725A (ja) 2007-01-19 2021-03-08 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2023049966A Pending JP2023078424A (ja) 2007-01-19 2023-03-27 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2025170793A Pending JP2025185093A (ja) 2007-01-19 2025-10-09 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009546577A Ceased JP2010516707A (ja) 2007-01-19 2008-01-22 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2016096016A Pending JP2016147905A (ja) 2007-01-19 2016-05-12 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2018058012A Pending JP2018111717A (ja) 2007-01-19 2018-03-26 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2021036134A Pending JP2021098725A (ja) 2007-01-19 2021-03-08 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2023049966A Pending JP2023078424A (ja) 2007-01-19 2023-03-27 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2025170793A Pending JP2025185093A (ja) 2007-01-19 2025-10-09 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Country Status (8)

Country Link
US (7) US8067532B2 (enExample)
EP (2) EP2109619B1 (enExample)
JP (7) JP2010516707A (enExample)
KR (4) KR101775929B1 (enExample)
CN (3) CN101675067B (enExample)
AU (1) AU2008206077A1 (enExample)
CA (2) CA2675665C (enExample)
WO (1) WO2008089491A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CN101668421B (zh) 2006-11-16 2014-05-21 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
WO2008089491A2 (en) * 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
WO2010111533A2 (en) * 2009-03-25 2010-09-30 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
ES2729051T3 (es) 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
WO2012170955A1 (en) 2011-06-08 2012-12-13 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
US20150038435A1 (en) * 2012-03-01 2015-02-05 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2916222C (en) 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2986774A1 (en) 2015-05-29 2016-12-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
JP2019500338A (ja) * 2015-12-02 2019-01-10 アンスティテュー・ナシオナル・ドゥ・ラ・ルシェルシュ・アグロノミクＩｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ａｇｒｏｎｏｍｉｑｕｅ 抗菌活性を有する新規ペプチド及びペプチド中におけるｌ型残基をｄ型アミノ酸に変換することができる新規酵素
US10654894B2 (en) 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
KR101772449B1 (ko) 2016-12-27 2017-08-30 주식회사 하이센스바이오 신규한 펩타이드
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
MX2020010071A (es) * 2018-03-29 2021-01-08 Contrafect Corp Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
JP7097465B2 (ja) 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
GB201903873D0 (en) * 2019-03-21 2019-05-08 Univ Nottingham Enhanced transfection
CN114096554A (zh) 2019-07-02 2022-02-25 Ａｇｃ株式会社 肽及其制造方法
JP7725466B2 (ja) 2019-11-13 2025-08-19 アムニクス ファーマシューティカルズ， インコーポレイテッド バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
US20230125482A1 (en) * 2020-03-24 2023-04-27 Young Therapeutics, Llc Protein kinase c modulators
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses
EP4406961A4 (en) 2021-09-22 2025-11-05 Agc Inc PEPTIDE
KR102380732B1 (ko) 2021-09-23 2022-04-04 엘이솔루션 주식회사 축산분뇨처리시스템
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615977A (en) * 1898-12-13 Car-fender
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
AU741546B2 (en) * 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US20030108539A1 (en) 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2001060837A2 (en) * 2000-02-16 2001-08-23 Northwestern University Polypeptoid pulmonary surfactants
IL137290A0 (en) 2000-07-13 2001-07-24 Asher Eldad Ben An electronic circuit for reducing the danger of exposure to radiation from a transmitter
JP3710368B2 (ja) 2000-09-25 2005-10-26 シャープ株式会社 積層フィルムの製造方法
IL155204A0 (en) * 2000-10-02 2003-11-23 Arizeke Pharmaceuticals Inc Compositions and methods for the transport of biologically active agents across cellular barriers
US20020168354A1 (en) * 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
CA2434643C (en) * 2001-01-18 2013-10-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of.delta.pkc
AU2002240312A1 (en) * 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
AU2003236096A1 (en) * 2002-04-11 2003-10-20 Mochida Pharmaceutical Co., Ltd. Peptide chemically modified with polyethylene glycol
WO2003089456A2 (en) * 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
AU2003294401C1 (en) * 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
WO2004076621A2 (en) 2003-02-27 2004-09-10 Yeda Research And Development Co. Ltd. Compositions of nucleic acids for treating and detecting influenza virus
US7482016B2 (en) * 2003-03-19 2009-01-27 The J. David Gladstone Institutes Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
ES2351976T3 (es) * 2003-04-29 2011-02-14 Avi Biopharma, Inc. Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.
CA2549052A1 (en) * 2003-12-11 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
EP1784483A2 (en) 2004-08-02 2007-05-16 The Board Of Trustees Of The Leland Stanford Junior University Peptide sequence for modulation of delta protein kinase c
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
JP4596391B2 (ja) 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
CN104017083A (zh) * 2005-04-15 2014-09-03 亚利桑那癌症治疗公司 用于治疗转移性癌症的治疗肽
JP5269596B2 (ja) * 2005-09-19 2013-08-21 カイ ファーマシューティカルズ インコーポレーティッド 血管新生のプロテインキナーゼｃペプチドモジュレーター
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2007143119A2 (en) * 2006-06-01 2007-12-13 The Board Of Trustees Of The Leland Stanford Junior University Method of preventing progression of hypertension-induced heart failure with pkc peptides
US7851587B2 (en) * 2006-10-02 2010-12-14 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the C2 domain of epsilon PKC
CN101668421B (zh) * 2006-11-16 2014-05-21 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
WO2008089491A2 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
CN101678063B (zh) * 2007-01-19 2012-12-19 凯制药公司 使用ε抑制剂化合物减轻疼痛的方法

Similar Documents

Publication Publication Date Title
JP2014224126A5 (enExample)
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
RU2021134101A (ru) Модифицированная j-цепь
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
JP2015514395A5 (enExample)
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
UA118167C2 (uk) Пептид та його застосування
MX2021007020A (es) Dominios variables de inmunoglobulina mejorados.
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
JP2015525217A5 (enExample)
JP2015513533A5 (enExample)
JP2014193892A5 (enExample)
MX393332B (es) Péptidos de tránsito dual para el direccionamiento a polipéptidos.
WO2015138907A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
PH12014501083A1 (en) Anticancer fusion protein
JP2015038108A5 (enExample)
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
NZ609216A (en) Anticancer fusion protein
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
JP2014525439A5 (enExample)
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
JP2010265269A5 (enExample)